Company family
Merck: medicine shortages
As of 2 Nov 2026, 10 Merck products have a reported shortage across 2 countries, covering 7 medicines.
Products short10rank #183 of 464
Medicines7active ingredients
Countries2/16
New in 90 days00 vs market pace
Typical duration8.0 yearsmedian so far
Manufacturing25%demand-driven 50%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Aprepitant | 3 | not given | Not stated | 12/16 | |
| Temozolomide | 2 | 23 Nov 2026 | Increased demand | 6/16 | |
| Bcg Vaccine | 1 | 19 Oct 2018 | Other | 3/16 | |
| Caspofungin | 1 | not given | Not stated | 5/16 | |
| Ertapenem | 1 | not given | Not stated | 4/16 | |
| Posaconazole | 1 | not given | Not stated | 6/16 | |
| Somatropin | 1 | 6 Nov 2026 | Manufacturing problem | 4/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.